Randomized Study of Larotaxel + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer.

Trial Profile

Randomized Study of Larotaxel + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Larotaxel (Primary) ; Cisplatin; Gemcitabine
  • Indications Bladder cancer; Urogenital cancer
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms CILAB
  • Sponsors Sanofi
  • Most Recent Events

    • 21 Apr 2012 Additional trial location added as reported by European Clinical Trials Database.
    • 06 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 Feb 2011 Planned end date changed from 1 Feb 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top